We conducted a prospective subgroup analysis of the Vax-On-Third-Profile study to investigate whether dynamic changes in peripheral blood lymphocytes following the third dose of tozinameran have an impact on clinical outcomes of advanced cancer patients receiving anti-PD-1/PD-L1 agents. Here, CD274 is linked to cancer.